Companies: 48,687 Total Market Cap: 126499770696275.11

Haleon plc

LON-HLN
Healthcare Drug Manufacturers - Specialty & Generic
Rank #444
Market Cap 46.62 B
Volume 9.42 M
Price 537.07
Change (%) 3.91%
Country or region United Kingdom United Kingdom

Haleon plc's latest marketcap:

46.62 B

As of May 2, 2025, Haleon plc's market capitalization has reached $46.62 B. According to our data, Haleon plc is the 444th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 46.62 B
Revenue (ttm) 14.94 B
Net Income (ttm) 1.92 B
Shares Out 9.02 B
EPS (ttm) 0.21
Forward PE 20.82
Ex-Dividend Date April 24, 2025
Earnings Date July 31, 2025
Market Cap Chart
Data Updated: May 2, 2025

Haleon plc's yearly market capitalization.

Haleon plc has seen its market value grow from £30.23 B to £33.97 B since 2022, representing a total increase of 12.38% and an annual compound growth rate (CAGR) of 5.14%.
Date Market Cap Change (%)
April 28, 2025 £33.97 B -0.58%
December 31, 2024 £34.17 B 15.03%
December 29, 2023 £29.70 B -1.74%
December 30, 2022 £30.23 B

Company Profile

About Haleon plc

Haleon plc, together with its subsidiaries, is a global leader in consumer healthcare, specializing in the research, development, manufacture, and sale of a diverse range of products. The company operates across multiple regions, including North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.

Product Portfolio

Haleon offers a wide variety of consumer healthcare products under well-known brands:

  • Oral Health: Sensodyne, Polident, Parodontax, Aquafresh, and Biotene for toothpastes, mouthwashes, and denture care.
  • Vitamins & Supplements: Centrum, Emergen-C, and Caltrate for nutritional support.
  • Respiratory Care: Otrivine, Theraflu, and Flonase for cold, flu, and allergy relief.
  • Pain Relief: Voltaren, Panadol, and Advil for anti-inflammatory and pain management.
  • Digestive Health: TUMS, ENO, and Fenistil for antacids and antihistamine solutions.

Company Background

Originally founded in 1715, Haleon plc was formerly known as DRVW 2022 plc before rebranding in February 2022. The company is headquartered in Weybridge, United Kingdom, and continues to be a trusted name in consumer healthcare worldwide.

Frequently Asked Questions

As of May 2, 2025, Haleon plc (including the parent company, if applicable) has an estimated market capitalization of $46.62 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Haleon plc global market capitalization ranking is approximately 444 as of May 2, 2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region United Kingdom
Founded 1715
IPO Date n/a
Employees 24,561
CEO Brian McNamara
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Address The Heights
Weybridge, KT13 0NY
United Kingdom
People Also Watch
HDB
73.61 1.72%
SHA-600036
5.60 1.72%
IBN
34.18 1.72%
TADAWUL-1120
25.68 1.72%